Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

NCT06591793 is registered in ClinicalTrials.gov with AAVantgarde Bio Srl as lead sponsor.

NCT NCT06591793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06591793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
Lead sponsor
AAVantgarde Bio Srl
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 2, 2024
Completion date
July 31, 2029
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

usher syndrome, type 1b